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Abstract
Hostile physiological environments such as hypoxia
and acidic extracellular pH, which exist in solid tumors,
may promote invasion and metastasis through in-
flammatory responses and formation of eicosanoids.
Here, we have investigated the effects of the anti-
inflammatory agent indomethacin on the invasion and
metabolism of the human breast cancer cell line MDA-
MB-435 in Dulbecco’s Modified Eagles (DME)-based
or Roswell Park Memorial Institute (RPMI)–based cell
medium, using a magnetic resonance–compatible in-
vasion assay. Indomethacin treatment significantly re-
duced the invasion of MDA-MB-435 cells independent
of the culture and perfusion conditions examined. Sig-
nificant changes were detected in levels of intracellular
choline phospholipid metabolites and in triglyceride
(TG) concentrations of these cells, depending on indo-
methacin treatment and basal cell medium used. Addi-
tionally, genetic profiling of breast cancer cells, grown
and treated with low-dose indomethacin in cell culture
using an RPMI-based medium, revealed the upregu-
lation of several genes implicating cyclooxygenase-
independent targets of indomethacin. These data
confirm the ability of an anti-inflammatory agent to
reduce breast cancer invasion and demonstrate, de-
pending on cell culture and perfusion conditions,
that the indomethacin-induced decrease in invasion
is associated with changes in choline phospholipid
metabolism, TG metabolism, and gene expression.
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Introduction
Solid tumors, including breast cancers, are often character-
ized by hypoxia, extracellular acidosis, and nutrient depri-
vation [1]. Similar to wounds, these characteristics of the
tumor microenvironment can evoke an inflammatory re-
sponse [2–4]. Not surprisingly, solid tumors frequently ex-
hibit increased levels of pro-inflammatory molecules, such
as prostaglandins, that are secreted by tumor cells, tumor-
associated stromal cells, and inflammatory cells [5,6]. These
prostaglandins can impact cancer cell motility, invasion, vascu-
larization, and metastatic dissemination [6–8]. Prostaglandins
are synthesized from arachidonic acid by the action of cyclooxy-
genases (COXs) [5,6], and increased expression of COX-2
is also frequently observed in tumors [7]. Nonsteroidal anti-
inflammatory drugs (NSAIDs) such as indomethacin reduce
inflammation by inhibiting COX activity [9], and clinical findings
of more than a decade have established that NSAIDs can
prevent an array of cancers, including estrogen receptor–
positive breast cancer [10]. Free arachidonic acid is formed
from the breakdown of membrane phospholipids by phospho-
lipases, such as phospholipases A2, C, and D, in response to
mechanical, chemical, and physical stimuli [11,12]. Therefore,
prostaglandin and eicosanoid biosynthesis and membrane
choline phospholipid metabolism are closely coupled [11,12].
We have previously observed that increased intracellular
phosphocholine (PC) and total choline [tCho; free choline +
PC + glycerophosphocholine (GPC)] were associated with
increased malignancy [13,14]. We also observed that treat-
ment of breast cancer cells with indomethacin significantly
reduced intracellular PC levels and increased intracellular
GPC levels toward levels typical of less malignant human
mammary epithelial cells (HMECs) [15–17]. Recently, we
also investigated the contribution of the anabolic and cata-
bolic pathways to the altered metabolic phospholipid profile
following treatment of MDA-MB-231 breast cancer cells and
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nonmalignant immortalized MCF-12A cells with 300 mM
indomethacin for 3 hours [18]. These studies revealed that
short-term, high-dose indomethacin treatment significantly
altered the genetic profile of treated cells [18].
To further understand the role of COX and choline phos-
pholipid metabolism in breast cancer invasion, here, we in-
vestigated the effect of long-term low-dose indomethacin on
breast cancer cell invasion using a magnetic resonance
(MR)–compatible cell perfusion assay, theMetabolic Boyden
Chamber (MBC), to dynamically track invasion and me-
tabolism. The ability of the MBC assay to measure invasion
and cellular metabolism under controlled environmental con-
ditions in long-term, MR experiments has been previously
validated using three prostate and three breast cancer cell
lines preselected for differences in invasive behavior [19,20].
This assay employs extracellular matrix (ECM) gel, which
is derived from Engelbreth-Holm-Swarm murine sarcoma
and is composed primarily of laminin, collagen type IV,
heparan sulfate proteoglycan, and entactin as a barrier for
cellular invasion (i.e., cellular migration through and pro-
teolytic degradation of ECM).
The incorporation of slow-release indomethacin pellets
into the assay resulted in a significant reduction in ECM gel
degradation by cancer cells compared to controls. Inter-
estingly, we observed that perfusing cells with Roswell Park
Memorial Institute (RPMI) or DME as basal cell culture me-
dium also altered the ability of these cells to degrade ECM.
Invasion and ECM degradation were enhanced for cancer
cells maintained in an RPMI-based culture medium com-
pared to cells maintained in a DME-based culture medium.
Consistent with our previous observations, indomethacin
treatment induced changes in choline phospholipid metabo-
lites to resemble levels more typical of nonmalignant cells.
Additionally, intracellular mobile lipid levels increased as a
result of indomethacin treatment.
In addition to nonspecific COX inhibition, indomethacin
has several other effects. It can bind and activate peroxi-
some proliferator-activated receptor gamma (PPARg), stimu-
late NAG-1 expression and proapoptotic activity, and cause
apoptosis by releasing cytochrome c and apoptosis-inducing
factors and by caspase activation [5,7]. In addition, it has
been shown to activate carbonic anhydrase I and carbonic
anhydrase II isozymes in a dose-dependent manner, to down-
regulate b-catenin/TCF signaling in colorectal cancer cells,
and to act as a mitochondrial uncoupler [5,7].
To further understand the mechanisms underlying the
functional changes in invasion and metabolism detected in
our studies, we used oligonucleotide microarray technology
to determine changes in gene expression levels induced by
indomethacin treatment in RPMI-based cell culture. Consis-
tent with previous studies [21], we found that GDF15, a di-
vergent member of the TGF-b superfamily, was upregulated
by indomethacin treatment. The GDF15 gene encodes for
a protein that is involved in differentiation, apoptosis, and
other biologic functions through autocrine or paracrine sig-
naling [21]. The expression of GDF15 was shown to be
COX-independent and p53-independent in several cancer
cell lines [22]. In addition to GD15, changes in several COX-
independent genes were identified in microarray analysis,
suggesting that, in addition to COX inhibition, other mecha-
nisms may play a role in the reduced invasion and altered
metabolism observed in this study. Our data support the use
of anti-inflammatory agents in breast cancer management
and prevention.
Materials and Methods
Cells and Cell Culture
Experiments were performed with the human breast can-
cer cell line MDA-MB-435, which was originally isolated from
the pleural effusion of a 31-year-old female with metastatic
ductal adenocarcinoma of the breast and established in
cell culture [23]. MDA-MB-435 breast cancer cells were
cultured in plastic tissue culture at 5% CO2 in air, 37jC, and
90% humidity using two different cell culture media: DME
plus supplements (DMEC) and RPMI 1640 plus supple-
ments (RPMIC). The cell culture medium DMEC was com-
posed of DME with 25 mM glucose and 4 mM L-glutamine
but without sodium pyruvate (Invitrogen Life Technologies,
Carlsbad, CA) supplemented with 9% fetal bovine serum
(FBS; Sigma-Aldrich, St. Louis, MO), 90 U/ml penicillin
(Invitrogen Corp., Grand Island, NY), and 90 mg/ml strepto-
mycin (Invitrogen Corp.); RPMIC consisted of RPMI 1640
(Sigma-Aldrich) supplemented with 9% FBS, 90 U/ml peni-
cillin, and 90 mg/ml streptomycin.
Three days before the MR experiments, MDA-MB-435
cells were seeded on Biosilon (Nunc, Denmark) beads at a
cell density of 3 106 cells per 0.5ml ofmicrocarriers in non–
cell culture Petri dishes (Labtec, Nunc, Denmark) and grown
adherently to approximately 80% to 90% confluency using
either DMEC or RPMIC. MDA-MB-435 cells on Biosilon beads
were counted at the beginning and at the end of the MR
experiments, as described previously [24]. Briefly, approxi-
mately 0.5 ml of cell-covered beads was incubated in 1 ml
of 0.1 M citric acid containing 0.1% (wt/vol) crystal violet
for 1 hour at 37jC, thus lysing the cells and releasing the
nuclei. Subsequently, the nuclei were diluted and counted
with a hemocytometer.
For GeneChip (Affymetrix, Santa Clara, CA) microarray
experiments, 3  106 MDA-MB-435 cells were seeded per
100-mm cell culture dish using 15 ml of RPMIC. Following
attachment overnight, the cell culture medium was ex-
changed. Cells from one treatment dish containing one
21-day-release biodegradable indomethacin pellet (0.5 mg/
pellet, MW indomethacin = 357.79 g/mol; Innovative Research
of America, Sarasota, FL) and from one control dish were
used to isolate RNA. The dishes were placed at 5% CO2 in
air, 37jC, and 90% humidity for 48 hours. A single pellet
was used to achieve an indomethacin concentration compa-
rable to that of the cell perfusion system. Two independent
experiments were performed.
MBC Assay
Details of MBC assay, which was developed to non-
invasively study cancer cell invasion and cancer cell
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metabolism, have been previously described in Pilatus et al.
[25]. Modifications incorporated for the current study are
described here.
MR-compatible cell perfusion system A schematic of a
sample preparation is shown in Figure 1. The sample con-
sisted of different layers containing filter material, cell-
covered beads, a home-built chamber filled with ECM gel
(Sigma-Aldrich), perfluorocarbon-doped alginate beads, and
indomethacin pellets in treatment experiments.
The home-built chamber consisted of an outer chamber
made from porous filter material (polyethylene; Small Parts,
Inc., Miami Lakes, FL) and an inner chamber composed of
a polycarbonate membrane (Millipore, Bedford, MA) fixed to
a Delrin ring (McMater-Carr Supply Company, Chicago, IL).
Cold liquid ECM gel (100 ml, 8.8 mg/ml protein, 4jC) was
pipetted into this chamber and placed at 37jC to polymerize
and form a well-defined layer (Figure 1). Cell-covered beads
were layered around the ECM gel chamber in a customized
10-mm nuclear magnetic resonance (NMR) tube (Wilmad
Ltd., Buena, NJ) that had a reinforced open base to ac-
commodate the outflow line of the cell perfusion system
(Figure 1). As shown in Figure 1, layers of perfluorocarbon-
doped alginate beads were interspersed in the upper
and lower cancer cell layers to monitor oxygen tension in
the sample using 19F MR relaxometry. In some experi-
ments, perfluorocarbon was added to the ECM gel to mea-
sure oxygen tension in the ECM layer. The preparation of
perfluorocarbon-doped alginate beads and the measure-
ment of oxygen tension using 19F MR relaxometry have
been described previously in detail by Pilatus et al. [25,26].
In treatment experiments, two or three 21-day-release bio-
degradable indomethacin pellets (0.5 mg/pellet) were posi-
tioned in the upper cell layer approximately 4 mm above the
ECM gel (Figure 1).
The sample was perfused continuously with either DMEC
plus 10 mM HEPES (DMECP) or RPMIC plus 10 mM HEPES
(RPMICP) (Sigma, St. Louis, MO). The flow rate of the
f 410-ml recirculating perfusion medium was approximately
1 ml/min. Sample temperature was maintained at 37jC, and
the oxygen tension in the sample was maintained above 10%.
MR data acquisition The MR experiments were performed
on a GE Omega 400 NMR spectrometer equipped with
shielded triple-axis gradients (130 G/cm maximum). MR
data were acquired using a home-built radiofrequency probe
consisting of a broadband coil for 31P MR spectroscopy and
a second coil tunable to 1H or 19F frequency.
The following MR data sets were acquired every 12 hours,
throughout the duration of an experiment that typically lasted
3 days [25]. T1-weighted
1H MR imaging was performed
to evaluate the sample preparation, to visualize the geome-
try of the ECM gel, and to detect changes in its integrity
due to invasion and degradation (Figure 1, right panel ).
A one-dimensional (1D) 1H profile of intracellular water
was acquired along the length of the sample (z-axis), using
diffusion-weighted 1D 1H MR imaging to suppress extracel-
lular water signal [25]. This profile, acquired with a spatial
resolution of 31.25 or 62.5 mm, was used to derive a quantita-
tive index of cell invasion.
Energy metabolites, pH, and the choline phospholipid
metabolites PC and GPC were obtained from global 1D
31P NMR spectra.
Intracellular levels of tCho, total creatine (tCr; creatine +
phosphocreatine), and lactate + triglyceride (LacTG) were
derived from global 1D 1H MR spectra acquired with diffusion
Figure 1. Schematic display of the sample structure (center), which can be identified clearly in the representative T1-weighted
1H MR image on the right. The
photograph on the top left shows a representative Biosilon bead covered with MDA-MB-435 cells. Control experiments were performed without pellets or unloaded
pellets. In experiments with indomethacin treatment, two or three biodegradable 21-day slow-release pellets were added to the upper cell layer approximately 4 mm
above the ECM gel. The released indomethacin concentrations calculated for the total medium volume of approximately 420 ml in the perfusion system were
f 0.48 mol/(l  24 hours) for three pellets and f 0.32 mol/(l  24 hours) for two pellets of indomethacin. The two arrows, marked 1 and 2, reflect the region
integrated to obtain Ip(t) and Ip,7 mm(t), as defined in Eq. (1). The invasion index reflects a composite of cell migration and ECM degradation.
224 Indomethacin Reduces Invasion and Alters Metabolism Ackerstaff et al.
Neoplasia . Vol. 9, No. 3, 2007
weighting and CHEmical Shift Selective (CHESS) water
suppression [25]. Diffusion-weighted 1D 1H MR spectra,
obtained without water suppression, were used to deter-
mine cell proliferation because the increase in slow-diffusing
water, which represents intracellular water, was directly pro-
portional to the number of cells. A cell count at the beginning
and at the end of each MR experiment confirmed cell growth,
indicating the absence of significant cell swelling or shrink-
age. To quantify the contribution of lactate (Lac) and triglyc-
erides (TGs) to the LacTG signal at 1.3 ppm in the global
1H MR spectra, we also acquired diffusion-weighted 1D
1H MR spectra using a spin echo–based pulse sequence
with an echo time of 136 milliseconds and Lac editing [27].
Localized 1D 1H chemical shift imaging (CSI) MR spectra
with and without CHESS water suppression were acquired
to obtain metabolic information from 310-mm-thick slices
along the z-axis of the sample [25]. Data from slice-selective
1D 19F inversion recovery experiments were used to calcu-
late oxygen tension in slices containing perfluorocarbon, as
described previously [26]. Localized 1D 1H CSI and 19F MR
spectra were acquired every 24 hours.
MR data processing and analyses Proton MR images and
profiles of cellular water were processed using software
provided with the spectrometer and exported for further
analysis. All MR spectra were processed and analyzed using
XsOsNMR, a postprocessing and quantitation package
programmed in Interactive Data Language (ITT, Boulder,
CO). XsOsNMR was developed and kindly provided by Dr.
D. C. Shungu and X. Mao (Hatch NMR Research Center,
Columbia University College of Physicians and Surgeons,
New York, NY).
T1-weighted
1H MR images were zero-filled once in the
phase-encoding dimension followed by two-dimensional (2D)
magnitude calculation. 1D profiles of intracellular water were
zero-filled once (resulting in a spatial resolution of 15.6 or
31.25 mm), multiplied by a combination of exponential and
Gaussian functions in the time domain, followed by a mag-
nitude calculation of Fourier-transformed echo.
The profiles of intracellular water were used to quantify
the number of cancer cells that invaded the ECM gel and to
derive an index of invasion. The invasion index I(t) at time
t was calculated as follows:
IðtÞ ¼ Ip;7 mmðtÞ
IpðtÞ 
Ip;7 mmðt1Þ
Ipðt1Þ ð1Þ;
where Ip,7 mm(t) is the integral value of the signal at time t,
obtained by integrating intracellular water signal over a 7-mm
region starting at the base of theECMgel chamber, and Ip(t) is
the integral for the entire diffusion-weighted profile at time t.
The first contact of cancer cells with the ECM gel during the
loading of the sample was defined as the zero time point, and
t1 defines the first MR data set acquired after loading.
After applying an exponential line-broadening factor of
15 Hz to the free induction decay (FID) of 1D 31P MR spectra
and 8 Hz to the FID of 1D 1H MR spectra, the resulting FIDs
were Fourier-transformed, and a zero-order phase correc-
tion was applied. Spectroscopic imaging data were pro-
cessed by applying a Hamming filter in the phase-encoding
dimension and an exponential line broadening of 8 Hz in
the time domain, followed by 2D Fourier transformation and
phase correction.
Signals of interest in the 31P and 1HMR spectra were fitted
in the time domain using an algorithm combining linear least
squares and nonlinear least squares fitting routines. Me-
tabolite levels in the 31P spectra [met31P(t)] at time t were
calculated as follows:
½met31PðtÞ ¼ ImðtÞ
IpðtÞ

Imðt1Þ
Ipðt1Þ ð2Þ;
where met31P is the normalized relative metabolite level and
Im is the integral of the metabolite signal. The pH was
calculated based on the equation: pH = 6.66 + log10[(DPi 
0.729) / (3.22 DPi)], where DPi = chemical shift of inorganic
phosphate [28]. Metabolite levels in the 1D 1H MR spectra
relative to the number of cells [met1H(t)] were calculated as:
½met1HðtÞ ¼ ImðtÞ
IcellðtÞ ð3Þ;
where met1H is the relative metabolite concentration in the
proton MR spectra, Im is the integral of the metabolite signal
in the 1H MR spectra, and Icell is the integral of the cor-
responding unsuppressed intracellular water signal at time
t, which is used to account for cell growth during the time
course of the experiment. Temperature was calculated from
the chemical shift difference between tCho and intracellular
water in the 1H MR spectra [29,30]. Both Ip and Icell are
proportional to the number of cells at time t and represent
cell growth during the MR experiment, as was validated
from nuclei counts of the cells on Biosilon beads at the start
and at the end of the MR experiments.
Fluorine MR spectra acquired during the 19F inversion
recovery experiment were processed and analyzed as de-
scribed in detail by Pilatus et al. [26].
Values presented as mean ± SE were averaged over
three independent experiments (n = 3) for each condition,
unless otherwise stated. The Mann-Whitney U test was
performed to test for statistically significant differences (P <
.05) between treated and untreated conditions using JMP IN
5.1 (Thompson Learning; SAS Institute, Inc., Belmont, CA).
GeneChip Microarray Experiments
Isolation of total RNA and human genome array Total
cellular RNA of MDA-MB-435 cells were isolated using the
RNeasy Mini Kit (Qiagen, Inc., Valencia, CA). Briefly, MDA-
MB-435 cells were washed twice in phosphate-buffered
saline. The cells were scraped in 600 ml of RLT lysis buffer
containing 6 ml of b-mercaptoethanol and homogenized using
QIAshredder homogenizer spin columns (Qiagen, Inc.). The
samples were diluted 1:2 with 70% ethanol and applied to
RNeasy mini columns to capture RNA. Following DNase
digestion and washing, RNA was eluted from RNeasy mini
columns and quantified, and RNA purity was evaluated.
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An Affymetrix GeneChip Human Genome U133 Plus 2.0
Array was used to analyze the expression levels off 47,400
transcripts, which represent 38,500 genes. RNA labeling and
microarray hybridization were performed by the Johns Hop-
kins Medical Institutions Microarray Core Facility (Dr. F. M.
Murillo; The Johns Hopkins University School of Medicine,
Baltimore, MD).
Briefly, RNA underwent quality control to confirm that
all samples had optimal rRNA ratios (1:2 for 18S and
28S, respectively) and clean run patterns using an Agilent
Bioanalyzer (Agilent, Santa Clara, CA). Then, 5 mg of pure
total RNA was converted to single-strand cDNA using oligo-
nucleotide probes containing 24 oligodeoxythymidylic acid
plus T7 promoter as primer (Proligo LLC, Boulder, CO) and
the SuperScript Choice System (Invitrogen Corp.). Fol-
lowing the synthesis of double-stranded cDNA and product
purification by phenol–chloroform extraction, biotinylated
antisense cRNA were generated by in vitro transcription
using the BioArray HighYield RNA Transcript Labeling Sys-
tem (ENZO Life Sciences, Inc., Farmindale, NY). Then, 15 mg
of biotinylated cRNA was fragmented in 100 mM Tris–
acetate pH 8.2, 500 mM potassium acetate, and 150 mM
magnesium acetate at 94jC for 35 minutes. Ten micrograms
of fragmented cRNA was hybridized to the Affymetrix U133
Plus 2.0 GeneChip array for 16 hours at 45jC under constant
rotation. Using an Affymetrix Fluidics Station 450, GeneChip
arrays were washed to remove nonhybridized cRNA and
incubated with streptavidin–phycoerythrin conjugate to stain
hybridized biotinylated cRNA. The staining was amplified
using IgG (goat) as a blocking reagent and biotinylated anti-
streptavidin antibody (goat) followed by a second staining
with streptavidin–phycoerythrin conjugate. Fluorescence
intensities were measured with an Affymetrix GeneChip
Scanner 3000. Basic image analysis for quality control
was performed. Fluorescence intensities were measured
with an Affymetrix GeneChip Scanner 3000, and a basic
image analysis for quality control was performed using the
Affymetrix GeneChip Operating System 1.1.1. Two indepen-
dent experiments each were run for treated and untreated
MDA-MB-435 cells.
Analysis of human genome array data Additional quality
control and analysis of human genome array data were per-
formed using the R environment (http://www.bioconductor.
org/, and Ref. [31]) at the Analysis Unit of the Johns Hopkins
Medical Institutions Microarray Core (Dr. Chunfa C. Jie, The
Johns Hopkins University School of Medicine).
A model-based quality control assessment of the Affy-
metrix GeneChip array was performed, followed by a princi-
pal components analysis. RNA degradation was statistically
evaluated. Human genome array data exhibited low RNA
degradation and excellent image quality (data not shown).
Based on the Affymetrix perfect match and mismatch
probe values, gene expression intensities were calculated
by Robust Multiarray Average [32]. Probe level data pro-
cessing included quantile normalization to reduce the ob-
scurity from variation between microarrays, which might be
introduced during sample preparation, manufacture, fluores-
cence labeling, hybridization, and/or scanning [33]. An em-
pirical Bayes method with g–g modeling was applied on
the resulting signal intensities to estimate the posterior prob-
abilities of the differential expression of genes between
untreated and indomethacin-treated MDA-MB-435 cells
[34–36]. The list of differentially expressed genes was pro-
duced by applying a posterior probability above .5 (i.e., the
posterior probability is larger than chance).
Quality control and statistical analysis were performed
using bioconductor packages (http://www.bioconductor.org/).
Results
The MBC allowed us to identify the invasive and metabolic
characteristics of MDA-MB-435 cells in response to low-
dose indomethacin treatment dynamically, longitudinally,
and noninvasively under controlled environmental condi-
tions. Indomethacin treatment reduced the rates of ECM gel
degradation, independent of the culture and perfusion media
used, as evident in the representative 1H MR images shown
in Figure 2, A and B. Quantitative time-dependent invasion
indices I(t) demonstrated that the invasion of MDA-MB-435
breast cancer cells maintained in DMECP was almost entirely
inhibited by indomethacin treatment (Figure 2C). For MDA-
MB-435 cells maintained in RPMICP, indomethacin treat-
ment significantly attenuated invasion but did not inhibit it
completely; reduction of invasion was comparable for the
two doses of indomethacin (Figure 2D).
Untreated and indomethacin-treated MDA-MB-435 cells
maintained in RPMICP exhibited a stronger invasive ca-
pability compared to MDA-MB-435 cells in DMECP under
equivalent conditions.
Because the profile of intracellular water is proportional
to the cell number at any given time, as was also apparent
from the cell count at the beginning and at the end of the MR
experiment, we calculated the fold change in cell number
during the time course of the MR experiments. The cell
density in the sample increased by approximately 3.6-fold
for control MDA-MB-435 cells, independent of the cell culture
medium used, whereas with indomethacin treatment, the
cell density increased by f 3-fold for cells in RPMICP and
byf 2.5-fold for cells in DMECP. Therefore, the difference in
invasive ability under the different conditions cannot be
explained by changes in cell proliferation.
Representative 1D 31P MR spectra of indomethacin-
treated and untreated MDA-MB-435 cells maintained in
DMECP or RPMICP acquired after 5 and 73 hours, respec-
tively, demonstrate the stability of pH during the time course
of the experiments (Figure 3). Although the experimental
setup did not permit the comparison of metabolite concen-
trations across separate experiments, we could track nor-
malized relative changes (Figure 4).
Nucleoside triphosphate levels corrected for cell number
and normalized to the starting value were not significantly
influenced by indomethacin treatment or change in basal
medium, but tended to decrease with time to between
60% and 80% of the starting value (Figure 4A). In experi-
ments performed with DMECP, GPC decreased within the
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first day to noise level in untreated MDA-MB-435 cells,
whereas GPC in indomethacin-treated cells remained con-
stant and declined to about 30% of the starting value only
after 2 days (Figure 4B). In the MR experiments performed
with RPMICP, the GPC signal did not rise significantly above
noise in either control or indomethacin-treated breast cancer
cells (Figure 3B).
Changes in intracellular PC levels over the time course
of MBC experiments using DMECP were not affected by
indomethacin treatment (Figure 4C). However, in MBC
experiments of MDA-MB-435 cells maintained in RPMICP,
indomethacin treatment significantly reduced intracellular
PC levels (Figure 4D).
Figure 5A shows a set of 1D 1H CSI MR spectra and
the corresponding region in the 1H MR image on day 2.
Composite MR signals representing the intracellular con-
centrations of metabolites such as tCho, tCr, and LacTG in
310-mm-thick slices were identified and quantified. LacTG
levels along the sample for untreated and treated MDA-MB-
435 cells perfused with DMECP or RPMICP are shown in
Figure 5, B–F. Figure 6A shows global cellular LacTG levels
of control and treated MDA-MB-435 cells in either DMECP or
RPMICP, obtained from global 1D
1H MR spectra using a
STEAM-based pulse sequence.
Intracellular LacTG levels increased during the time
course of the MBC experiments independent of the perfusion
Figure 2. T1-weighted
1H MR images (A and B) and invasion indices over
time (C and D) demonstrating the effect of indomethacin treatment and cell
culture medium on the degradation (A and B) and invasion (A–D) of ECM gel
by MDA-MB-435 breast cancer cells. Invasion includes components of cell
migration and ECM degradation. (A, a) Untreated MDA-MB-435 cells cultured
in DMEC and perfused in DMECP. (A, b) Indomethacin-treated (three pellets)
MDA-MB-435 cells cultured in DMEC and perfused in DMECP. (B, a) Un-
treated MDA-MB-435 cells cultured in RPMIC and perfused in RPMICP. (B, b)
Indomethacin-treated (three pellets) MDA-MB-435 cells cultured in RPMIC
and perfused in RPMICP. (C) DMECP: closed circles, control, n = 4; open
circles, three pellets of indomethacin, n = 3 ( zP = .16 for treated versus
untreated MDA-MB-435 cells). (D) RPMICP: closed circles, control, n = 3;
open circles, three pellets of indomethacin; open squares, two pellets of
indomethacin (*P < .05 for treated versus untreated MDA-MB-435 cells).
Values of invasion indices are presented as mean ± SE.
Figure 3. Representative 1D 31P MR spectra of the entire sample at the
beginning and at the end of an experiment. (A, a) DMECP, control. (A, b) DMECP,
globally released indomethacin concentration of 0.48 mol/(l 24 hours). (B, a)
RPMICP, control. (B, b) RPMICP, globally released indomethacin concentration
of 0.48 mol/(l  24 hours). Signal assignments: DPDE, diphosphodiester;
NADP(H), signal consisting of NAD+, NADH, NADP+, and NADPH; PCr,
phosphocreatine; NTP, nucleoside triphosphate; NDP, nucleoside diphosphate;
Pi, inorganic phosphate (ex, extracellular; in, intracellular).
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medium (Figures 5, B–F, and 6A). For untreated MDA-MB-
435 cells in DMECP, LacTG levels increased only until day 1
and leveled out, which was also reflected in the localized
1H MR spectra (Figures 5B and 6A). A comparison with
global Lac-edited 1H MR spectra suggests that both intra-
cellular Lac and TG were responsible for the increase in
intracellular LacTG with time (Figure 6, B and C). Typically,
intracellular metabolite levels appeared to be higher in MDA-
MB-435 cells maintained in DMECP than in cells in RPMICP
(Figures 5 and 6).
Intracellular tCho and tCr along the sample were unaf-
fected by indomethacin treatment, independent of the cell
culture and perfusion medium used (data not shown). How-
ever, indomethacin treatment significantly increased LacTG
in MDA-MB-435 cells maintained in RPMICP compared to
control cells, localized within and directly below the region of
the sample containing the indomethacin pellets (Figure 5,
D–F ). This localized LacTG increase as a result of ex-
posure to indomethacin was not reflected in the global 1D
1H MR spectra of MDA-MB-435 cells in RPMICP (Figure 6A).
Global Lac-edited 1D 1H MR spectra of MDA-MB-435 cells
in RPMICP revealed that, compared to control cells, indo-
methacin treatment significantly increased intracellular TG
(Figure 6C) but did affect intracellular Lac levels only for
MDA-MB-435 cells in RPMICP treated with two pellets of
indomethacin between days 1 and 2 (Figure 6B).
Global 1D 1H MR spectra of MDA-MB-435 cells perfused
with DMECP did not reveal any significant effect of indo-
methacin treatment on intracellular concentrations of tCho,
tCr, LacTG, Lac, or TG compared to control cells (Figure 6).
The absence of indomethacin-induced LacTG changes in
MDA-MB-435 cells in DMECP was echoed by only a marginal
effect on intracellular LacTG levels in localized MR spectra
(Figure 5, B and C).
Results frommicroarray analysis are displayed in Table 1.
Several genes were upregulated or downregulated by
48 hours of low-dose exposure of MDA-MB-435 cells to
indomethacin. Currently known functions of each of these
genes are also listed in this table. Most of these genes are
involved in amino acid metabolism, with only one gene
connected to fatty acid metabolism, indicating that the action
of indomethacin occurs mainly at the protein level rather than
through genetic modulation.
Discussion
Indomethacin treatment reduced the invasion of MDA-MB-
435 cells into ECMgel, irrespective of whether DME-based or
Figure 4. Relative changes in phosphometabolites during the time course of
the MR experiments. Values are presented as mean ± SE. (A) Relative
changes in -NTP for indomethacin-treated (three or two pellets of
indomethacin) and untreated MDA-MB-435 cells perfused with DMECP or
RPMICP. (B) Relative changes in GPC for treated (open circles, three pellets of
indomethacin, n = 3) and control (closed circles, n = 4) MDA-MB-435 cells
perfused with DMECP.
zP < .05 for indomethacin-treated versus untreated
MDA-MB-435 cells. (C) Relative changes in PC for control (closed circles,
n = 4) and indomethacin-treated (open circles, three pellets of indomethacin,
n = 3) MDA-MB-435 cells perfused with DMECP. (D) Relative changes in PC
for control (closed circles, n = 3) and indomethacin-treated (open circles, three
pellets of indomethacin, n = 3; open squares, two pellets of indomethacin,
n = 3) MDA-MB-435 cells perfused with RPMICP. *P < .05 for indomethacin-
treated versus untreated MDA-MB-435 cells. (*) Two time points where
untreated MDA-MB-435 cells were significantly different from cells treated
with two pellets of indomethacin, but not from cells treated with three pellets
of indomethacin.
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RPMI 1640–based medium was used for cell culture and cell
perfusion. These results are consistent with previous ob-
servations by Connolly and Rose [37], where treatment of
MDA-MB-435 cells with 55.9 mM indomethacin for 72 hours
reduced invasion, as measured in a modified Boyden
chamber assay. Indomethacin treatment of MDA-MB-435
cells suppressed cancer cell invasion to an even greater
extent in the presence of linoleic acid (LA), which stimulated
invasion by control cells [37]. Additionally, treatment with
20 mM indomethacin completely inhibited the LA-stimulated
MMP-2 activity of MDA-MB-435 breast cancer cells [38]. In
a subsequent in vivo study performed by Connolly et al.
[39], MDA-MB-435 tumors displayed reduced growth and
metastasis to the lung following treatment with indo-
methacin. In that study, indomethacin was administered in
drinking water at a concentration of 10 and 20 mg/ml, leading
to approximately 1.3 and 2.5 mg indomethacin/kg body
weight per day, respectively.
Figure 5. (A) Representative water-suppressed 1D 1H CSI MR spectra of 310-m-thick slices acquired along the sample 47 hours after loading, together with the
corresponding 1H MR image for MDA-MB-435 cells perfused with DMECP. (B–F) Relative levels of LacTG, along with the sample obtained for MDA-MB-435 cells.
Values presented as mean ± SE are from 1D 1H CSI spectra averaged over three experiments for each condition, unless otherwise stated. (B) Untreated, DMECP,
n = 4. (C) Three pellets of indomethacin, DMECP. (D) Untreated, RPMICP. (E) Two pellets of indomethacin, RPMICP. (F) Three pellets of indomethacin, RPMICP (d2;
average of n = 2). The base of the ECM gel chamber was defined as 0 mm. The empty region from 0 to 3 mm represents the filter material forming the base of the
ECM gel chamber. ECM = the thickness of the ECM gel at the start of the experiments; Indo = the approximate position of the indomethacin pellets in the upper cell
layer at the start of the MR experiments; d1, d2, d3 = elapsed time after the loading of cells (i.e., days 1, 2, and 3, respectively).
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The observation of reduced invasion in response to indo-
methacin treatment is not restricted to breast cancer cells
but has also been observed in other types of cancer cells
and tumor models. Reich and Martin [40] reported that
18 hours of treatment with 10 and 50 mM indomethacin re-
duced dose dependently the invasion of mouse melanoma
cells and a human fibrosarcoma cell line, as measured by a
Boyden chamber assay. Dose-dependent reduction in colla-
genase IV activity was also detected in these studies. In the
same study, the treatment of cells with the lipooxygenase
inhibitor esculetin induced similar effects, indicating that
COX and lipooxygenase pathways of arachidonic acid me-
tabolism play a role in cancer cell invasion.
Indomethacin treatment above 10 mM decreased migra-
tion and invasion in C3L5 murine mammary carcinoma cells,
and a 24-hour exposure to > 50 mM indomethacin led to loss of
viable cells [41]. Additionally, treatment with indomethacin
concentrations as low as 5 mM reduced PGE2 expression
levels. In these studies, the treatment of C3L5 cells with
50 mM indomethacin did not significantly influence MMP-2
and MMP-9 activities.
Wang et al. [42] reported that glioma cell invasion into
Matrigel (ECMatrix, Chemicon International, Temecula, CA)
was significantly reduced by high-dose treatment of indo-
methacin (500 mM), but not at a lower dose of 50 mM. Consis-
tent with changes in invasion, total MMP-2 and active MMP-2
levels in conditioned media were significantly reduced at an
indomethacin concentration of 500 mM but not at 50 mM. Cell
migration, however, remained unaffected even at doses of up
to 500 mM, and doses above 500 mM resulted in cytotoxicity.
Although previous studies have shown a dose dependent
reduction of invasion with indomethacin treatment for doses
above 10 mM [40–42], in our study, the invasion of MDA-MB-
435 cells exposed to indomethacin treatment was dose-
independent for the two doses of f 0.48 and f 0.32 mmol/
(l 24 hours) in the perfusate. One possible explanation may
be that cancer cell invasion becomes dose-dependent for
doses of indomethacin only beyond a threshold dose, which
may also depend on cell type. Indomethacin can also act as
a mitochondrial uncoupler, which lowers ATP generation
and reduces cell proliferation [7]. Cell growth tended to be
reduced by indomethacin treatment in our study. Because cell
proliferation was factored into the calculation of the invasion
index, changes in invasion observed in this study were in-
dependent of cell proliferation.
Our data also demonstrate the importance of basal medi-
um in influencing the ability of breast cancer cells to invade
and degrade ECM. Even though cell proliferation was com-
parable for the two media used, MDA-MB-435 cells were
significantly more invasive in RPMI than in DME. Studies
investigating cancer cell invasion often use serum-containing
media, growth factors, or conditioned media as chemo-
attractants [43]. To date, little is known about the effects of
basal medium composition on cancer cell invasion. Haugland
and Tysnes [44] used an in vitro coculture assay of tumor
spheroids and fetal rat brain cell aggregates as target tis-
sues to assess the invasive ability of three human glioma cell
lines cultured in a variety of defined cell culture media and
one serum-containing cell culture medium. The study found
that the invasive ability of the three cell lines was preserved
in all culture media that were able to support spheroid
growth, although to varying degrees. Interestingly, direc-
tional cell migration on a poly-D-lysine substrate was only ob-
served with the serum-containing culture medium, but not
with defined media. A comparison of the composition of
DME and RPMI 1640 revealed that the basal medium RPMI
1640 contained L-asparagine (anhydrase), L-aspartic acid,
L-glutamic acid, hydroxy-L-proline, D-biotin, p-amino-benzoic
acid, and vitamin B12, whereas these amino acids and
Figure 6. (A) Relative levels of LacTG over time obtained for MDA-MB-435
cells in DMECP or RPMICP. Values presented as mean ± SE are from global 1D
1H MR spectra acquired with a STEAM-based pulse sequence. (B and C)
Relative levels of Lac (B) and TGs (C) over time obtained for MDA-MB-435
cells in DMECP or RPMICP. Values presented as mean ± SE are from global 1D
1H MR spectra acquired with a spin echo–based pulse sequence and
Lac editing.
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Table 1. Fold Change (Fc) in the Gene Expression of MDA-MB-435 Cells Cultured in RPMIC in Response to Indomethacin Treatment.
Affymetrix Probe
Set ID*
Fc P UniGene ID*, Gene Symbol
(Gene Title)
Gene Ontology Biologic Process//Molecular
Function
Pathway (KEGG)y
230746_s_at 2.03 1.00 Hs.25590, STC1 (stanniocalcin 1) Calcium ion homeostasis (tca)//cell surface
receptor – linked signal transduction
(tca)//cell – cell signaling (tca)//response
to nutrients (tca)//hormone activity (tca)
209183_s_at 1.85 1.00 Hs.93675, C10orf10 (chromosome
10 open reading frame 10)
237631_at 1.82 1.00 Hs.195400, – (transcribed locus)
239870_at 1.71 .92 Hs.135283, SPATS1
(spermatogenesis-associated,
serine-rich 1)
200648_s_at 1.64 .63 Hs.518525, GLUL
(glutamate–ammonia ligase
(glutamine synthase))
Regulation of neurotransmitter levels
(not recorded)//glutamine biosynthesis
(ifa)//glutamine biosynthesis (not recorded)//
nitrogen compound metabolism (ifa)//
glutamate–ammonia ligase activity (ifa)//
ligase activity (ifa)
Glutamate metabolism,
peptidoglycan biosynthesis,
nitrogen metabolism, glutamate
receptor signaling pathway
(Ingenuity)
231894_at 1.63 .63 Hs.531176, SARS (seryl-tRNA
synthetase)
Protein biosynthesis (ifa)//protein biosynthesis
(tca)//seryl-tRNA aminoacylation (ifa)//tRNA
processing (tca)//RNA binding (tca)//
serine-tRNA ligase activity (ifa)//serine-tRNA
ligase activity (tca)//ATP binding (ifa)//ligase
activity (ifa)
Glycine, serine, and threonine
metabolism; aminoacyl-tRNA
biosynthesis
204285_s_at 1.64 .55 Hs.96, PMAIP1 (phorbol-12-
myristate-13-acetate– induced
protein 1)
212816_s_at 1.65 .81 Hs.533013, CBS (cystathionine
b-synthase)
Cysteine biosynthesis from serine (ifa)//
metabolism (ifa)//amino acid biosynthesis
(ifa)//cysteine biosynthesis through
cystathione (ifa)//cystathionine b-synthase
activity (tca)//lyase activity (ifa)
Gycine, serine, threonine
metabolism; selenoamino
acid metabolism
200924_s_at 1.66 .56 Hs.502769, SLC3A2 (solute carrier
family 3 (activators of dibasic
and neutral amino acid
transport), member 2)
Carbohydrate metabolism (ifa)//calcium ion
transport (non-(tca))//amino acid transport
(tca)//cell growth (non-(tca))//catalytic activity
(ifa)//a-amylase activity (ifa)//calcium–
sodium antiporter activity (tca)
Starch and sucrose metabolism
204286_s_at 1.67 .83 Hs.96, PMAIP1 (phorbol-12-
myristate-13-acetate– induced
protein 1)
202887_s_at 1.69 .60 Hs.523012, DDIT4 (DNA
damage– inducible transcript 4)
200670_at 1.70 .81 Hs.437638, XBP1 (X-box–binding
protein 1)
Transcription (ifa)//regulation of transcription,
DNA-dependent (ifa)//immune response
(tca)//transcription factor activity (tca)
Endoplasmic reticulum pathway
(Ingenuity)
219270_at 1.72 .95 Hs.155569, MGC4504
(hypothetical protein MGC4504)
221156_x_at 1.74 .97 Hs.285051, CCPG1 (cell cycle
progression 1)
218145_at 1.74 .89 Hs.516826, TRIB3 (tribbles
homolog 3 (Drosophila))
Activation of MAPK (inferred from direct
assay)//transcription (ifa)//regulation of
transcription, DNA-dependent (ifa)//protein
amino acid phosphorylation (ifa)//negative
regulation of protein kinase activity (ifsss)//
apoptosis (ifsss)//transcription corepressor
activity (ifsss)//protein kinase activity (ifa)//
protein kinase inhibitor activity (ifa)//protein
binding (inferred from physical interaction)//
protein binding (ifsss)//ATP binding (ifa)//
protein kinase binding (inferred from physical
interaction)//protein kinase binding (ifsss)
209146_at 1.80 .99 Hs.105269, SC4MOL
(sterol-C4-methyl oxidase– like)
Fatty acid metabolism (tca)//metabolism (ifa)//
sterol biosynthesis (ifa)//C4 methylsterol
oxidase activity (tca)//oxidoreductase
activity (ifa)
Cholesterol biosynthesis
(GenMAPP)
205194_at 1.80 .99 Hs.512656, PSPH (phosphoserine
phosphatase)
L-serine biosynthesis (ifa)//metabolism (ifa)//
amino acid biosynthesis (ifa)//magnesium
ion binding (ifa)//catalytic activity (ifa)//
phosphoserine phosphatase activity (ifa)//
phosphoserine phosphatase activity (tca)//
hydrolase activity (ifa)
Glycine, serine, and threonine
metabolism
232689_at 1.81 1.00 Hs.504501, LOC284561
(hypothetical protein
LOC284561)
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vitamins were absent in DME. However, most amino acids
and vitamins present in both basal media had a higher
concentration in DME. In RPMI 1640, Ca(NO3)24H2O was
the source of calcium and nitrate, whereas DME contained
ferric nitrate and calcium chloride, adding iron to inorganic
salt components. An additional component missing in DME
but present in RPMI 1640 was reduced glutathione, a potent
intracellular antioxidant [45]. In contrast, DME contained
2.25-fold more D-glucose than RPMI 1640. It has been
reported for a murine fibrosarcoma and a murine squamous
cell carcinoma cell line that complete glucose removal
from the culture medium increased invasion [46], indicating
a role for glucose availability in invasion. However, in our
study, bothmedia contained glucose and, based on the levels
of the energy phosphates b-NTP and PCr, cellular glucose
starvation was not evident in the MR experiments. These
data do demonstrate that any interpretation of the invasive-
ness of cancer cell lines must also take into consideration
medium and perfusion conditions. The exact components
that caused the increased invasion in cells cultured in RPMI-
based medium remain to be identified.
Low-dose indomethacin treatment of MDA-MB-435 cells
in DMECP attenuated the drop of GPC levels observed in
untreated cells over time and also decreased PC levels of
MDA-MB-435 cells in RPMICP. These data are consistent with
results obtained from HMEC extracts, intact breast cancer
cells, and extracts of rat stomach [15–18,47]. Proton MR
spectra obtained from HMEC extracts exhibited increased
GPC and decreased PC following treatment with indo-
methacin [16]. Consistent with the study on cell extracts, a
drop in PC and an increase in GPC were evident in intact
MDA-MB-231 cells within 80 minutes of exposing the cells
to 200 mM indomethacin [17]. Ramadan et al. [47] observed
that GPC increased in indomethacin-induced rat stomach
ulcers. Thus, increased GPC appears to be directly related
to indomethacin treatment.
An increase in GPC has been previously associated with
the reduced malignancy of HMECs in vitro and in vivo
Table 1. (continued )
Affymetrix Probe
Set ID*
Fc P UniGene ID*, Gene Symbol
(Gene Title)
Gene Ontology Biologic Process//Molecular
Function
Pathway (KEGG)y
217127_at 1.85 1.00 Hs.19904, CTH (cystathionase
(cystathionine g-lyase))
Amino acid biosynthesis (ifa)//cysteine
biosynthesis (ifa)//cystathionine g-lyase
activity (ifa)//lyase activity (ifa)
Glycine, serine, and threonine
metabolism; methionine
metabolism; cysteine
metabolism; selenoamino acid
metabolism; nitrogen metabolism
209921_at 1.91 1.00 Hs.6682, SLC7A11 (solute
carrier family 7 (cationic amino
acid transporter, y+ system)
member 11)
Protein complex assembly (not recorded)//
transport (ifa)//amino acid transport
(ifa)//cystine:glutamate antiporter activity
(tca)//amino acid permease activity (ifa)
221577_x_at 1.91 1.00 Hs.515258, GDF15 (growth
differentiation factor 15)
Signal transduction (tca)//TGF-b receptor
signaling pathway (tca)//cell – cell signaling
(tca)//cytokine activity (tca)//growth factor
activity (ifa)
217678_at 1.93 1.00 Hs.6682, SLC7A11 (solute carrier
family 7 (cationic amino acid
transporter, y+ system)
member 11)
Protein complex assembly (not recorded)//
transport (ifa)//amino acid transport
(ifa)//cystine:glutamate antiporter activity
(tca)//amino acid permease activity (ifa)
205475_at 2.52 1.00 Hs.7122, SCRG1 (scrapie
responsive protein 1)
Neurogenesis (tca)
226181_at 2.59 1.00 Hs.34851, TUBE1 (tubulin,
epsilon 1)
Microtubule-based movement (ifa)//
centrosome cycle (tca)//protein
polymerization (ifa)//GTPase activity
(ifa)//structural constituent of cytoskeleton
(tca)//GTP binding (ifa)
231202_at 2.62 1.00 Hs.42572, ALDH1L2 (aldehyde
dehydrogenase 1 family,
member L2)
One-carbon compound metabolism (ifa)//
biosynthesis (ifa)//oxidoreductase activity
(ifa)//hydroxymethyl, formyl, and related
transferase activity (ifa)//cofactor binding
(ifa)
205047_s_at 2.69 1.00 Hs.489207, ASNS (asparagine
synthetase)
Asparagine biosynthesis (ifa)//asparagine
biosynthesis (non-(tca))//glutamine
metabolism (ifa)//metabolism (ifa)//amino
acid biosynthesis (ifa)//asparagine synthase
(glutamine-hydrolyzing) activity (inferred
from direct assay)//asparagine synthase
(glutamine-hydrolyzing) activity (ifa)//ligase
activity (ifa)
Alanine and aspartate metabolism;
nitrogen metabolism
The global concentration of indomethacin released into 15 ml of cell culture medium over a period of 24 hours was 4.44 mmol/(l  24 hours).
Fc < 0 = downregulated genes; Fc > 0 = upregulated genes; P = probability of a gene being differentially expressed; tca = traceable author statement; ifa = inferred
from electronic annotation; ifsss = inferred from sequence or structural similarity.
*Gene annotations corresponding to the Affymetrix probeset ID are current as of June 2005.
yKEGG: www.kegg.com; Ingenuity: www.ingenuity.com; GenMAPP: www.genmapp.org.
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[13,48]. These findings agree with our observations that
decreased invasion of MDA-MB-435 cells was accompanied
by higher intracellular GPC levels.
LacTG levels increased in indomethacin-treated MDA-
MB-435 cells in RPMICP, but not DMECP, compared to control
cells. This increase was due to increased intracellular TG
levels, as intracellular Lac levels did not change significantly
with indomethacin treatment.
The increase in TGs observed here is consistent with an
earlier in vivo study by Comai et al. [49] where TG content
and number of lipid droplets increased in renal medullary
interstitial cells of indomethacin-treated rabbits. Increased
intracellular TGs have been associated with the induction of
apoptosis [50] and have been detected in response to differ-
entiation therapy [51]. The observed increase in intracellular
TGs during indomethacin treatment may be the result of both
the increased availability of free arachidonic acid and the
decrease in prostaglandins due to COX inhibition.
It has been observed in several human cancer cell lines
[52–56] and endothelial cells [57] that excess arachidonic
acid administered exogenously into the culture medium was
rapidly incorporated into TGs and, to a lesser extent, into
phospholipids, with only small amounts into diacylglycerides.
Additionally, as observed in human neuroblastoma cells,
the total TGmass per cell increased, whereas total phospho-
lipid content was not significantly affected [53]. These re-
sults, together with observations made by Spinedi [53] and
Blank et al. [58] on HL-60 cells, led to the hypothesis that
excess free arachidonate is incorporated into TGs through
the de novo biosynthesis of glycerolipids by acyl-CoA acyl-
transferases and that TGs are storage sites for excess cel-
lular arachidonate.
Microarray analyses revealed the downregulation of
5 genes and the upregulation of 19 genes following low-dose
treatment with indomethacin. Within the constraints of the
current study, none of the currently known direct targets
of invasion or metabolism was identified, suggesting that
changes in invasion-related enzymes did not occur at the
transcriptional level, at least for 2D culture. However, several
of the genes identified, such as SLC3A2 or GDF15, are in-
directly involved in both functions.
Of the five downregulated genes, the geneSTC1 has been
found to be upregulated in amajority of breast tumor samples
[59]. Here, indomethacin treatment reduced STC1 gene
expression byf 2-fold. However, Baek and Eling [21] have
shown an increased STC1 gene expression with COX in-
hibition in human colorectal cancer cells. It is possible that
differences in dosage or variability between cell lines may be
responsible for this contrasting result. The gene GLUL, also
downregulated by indomethacin treatment, encodes for glu-
tamine synthase—an enzyme whose upregulated expres-
sion has been associated with shorter disease-free survival
in patients with hepatocellular carcinoma [60].
Several upregulated genes identified in microarray data
have a broad-ranging impact on cellular pathways, such as
amino acid metabolism and molecular functions, and may
have played a role in the changes in invasion and metabo-
lism observed here.
Of these upregulated genes, CBS, CTH, SARS, and
PSPH encode for proteins that impact on serine metabo-
lism. The enzyme encoded by PSPH regulates the conver-
sion between L-serine and O-phospho-L-serine. The protein
encoded by SARS converts L-serine to L-seryl-tRNA/ser
and has been shown to induce the cell migration of a CC
chemokine receptor 3–transfected human embryonic kid-
ney epithelial cell line [61]. The protein encoded by CBS
converts L-serine to L-cystathionine or L-cysteine, with the
protein encoded by CTH handling the conversion between
L-cysteine and L-cystathionine, and vice versa. Additionally,
the proteins encoded by CBS and CTH promote conversion
from selenohomocysteine to selenocystathionine to seleno-
cysteine. The genes SLC3A2 and SLC7A11 encode for the
membrane proteins 4F2hc and xCt, which form a hetero-
dimeric complex exchanging extracellular anionic cystine for
glutamate with a stoichiometry of 1:1 sodium independently
[62]. It has been suggested that 4F2hc, a protein encoded by
SLC3A2, plays a role in integrin function and is involved in
multiple pathways related to cell growth, cell adhesion, and
malignant transformation [63]. In addition, glutamate syn-
thesis appeared to be affected by indomethacin treatment
because the genes ASNS and CTH encoding for proteins
involved in glutamate production were upregulated.
The increased expression of ASNS, TRIB3, and XBP1 by
indomethacin treatment indicated a response to endoplasmic
reticulum stress at the transcriptional level [64–66]. To what
extent these changes at the transcriptional level impact on
cell proliferation or growth arrest, apoptosis, or antiapoptosis
following indomethacin treatment requires further study. Low-
dose indomethacin treatment also upregulated two additional
genes PMAIP1 and DDIT4, which encode for proteins in-
volved in apoptosis [67,68].
GDF15, also known as GDF-15, MIC-1, MIC1, NAG-1,
PDF, PLAB, or PTGFB, encodes for a protein that is a
member of the transforming growth factor (TGF)-b super-
family and is involved in tissue differentiation and mainte-
nance. The GDF15 protein, macrophage inhibitory cytokine
1, has been shown to be elevated in the serum of patients
with metastatic prostate, breast, and colorectal carcinomas
[69]. The GDF15 protein is involved in apoptosis and other
biologic functions in an autocrine or a paracrine manner,
independent of COX regulation [21]. Indomethacin treat-
ment increased GDF15 mRNA levels dose dependently
and time dependently in human colorectal, breast, prostate,
lung epithelial, and oral cavity cancer cells [22,70]. The
GDF15 gene is regulated in response to a number of NSAIDs
in several cancer cell lines through COX-independent and
p53-independent mechanisms [22]. The primary role of
GDF15 in cancer cell invasion is yet to be determined.
In our study, treatment of MDA-MB-435 breast cancer
cells with 4.44 mmol/(l  24 hours) for 24 hours did not affect
MMP gene expression. It is possible that indomethacin may
inhibit MMP expression through repression of gene tran-
scription because treatment of lung cancer cells with 20
and 100 mM indomethacin for 24 hours reduced the pro-
moter activity of MMP-2 to f (80+10)% and f (20+2)% of
control, respectively [71]. Treatment of MDA-MB-231 cells
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with a short-term high dose of 300 mM indomethacin for
2 hours resulted in the underexpression or overexpression
of multiple genes involved in processes such as angiogene-
sis, apoptosis, cell adhesion, cell cycle regulation, cell differ-
entiation, cell motility, choline phospholipid metabolism, and
DNA repair [18]. Again, none of the known genes directly
involved in choline phospholipid metabolism was identified in
this study. Interestingly, there was no overlap in the changes
in gene expression profiles observed by Glunde et al. [18] for
short-term high-dose treatment of MDA-MB-231 cells and
long-term low-dose treatment of MDA-MB-435 cells in the
current study, which may be explained, in part, by differences
in cell type and dose.
In summary, we have shown here that a nonspecific
COX inhibitor, indomethacin, induced a profound reduction
in the ability of breast cancer cells to invade and degrade
ECM gel. Metabolic changes in choline phospholipids and
TGs more typical of differentiated HMECs were temporally
coincident with changes in invasion. Microarray data re-
vealed several molecular changes that may have played a
role in the reduced invasion and altered metabolism ob-
served here and could potentially represent novel COX-
independent target genes in the invasion pathway. Our data
strongly support the use of anti-inflammatory agents in re-
ducing breast cancer invasion.
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